IN RE Talis Biomedical Securities Litigation
Case Number:
3:22-cv-00105
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
February 12, 2024
Investors Win Class Cert. Against Failed COVID Test Maker
Investors suing biotech company Talis Biomedical Corp. have received class certification in a suit alleging the company hurt investors when trading prices sank a month after its initial public offering when the company failed to secure U.S. Food and Drug Administration approval for its flagship testing platform.
-
October 16, 2023
Investors In Maker Of Failed COVID Test Want Class Certified
A group of investors suing a biotech company that failed to launch a COVID-19 diagnostic test promoted in the run-up to the firm's IPO urged a California federal court to certify a class, arguing the move is called for because the number of affected shareholders is large and damages are likely too small for individual litigation.
-
May 01, 2023
Biotech Co. To Face Amended Investor Suit Over COVID Test
A California federal judge has declined to dismiss an amended investor complaint against a biotech company over issues with its COVID-19 test rollout, holding the revised suit plausibly alleges the defendants made false and misleading statements.
-
December 12, 2022
Biotech Co. Gets Investor Suit Over Failed COVID Test Tossed
A biotech company that was sued by investors over issues with its COVID-19 test rollout convinced a California federal judge to toss the suit after arguing that none of the statements identified by the plaintiffs in the complaint were false or misleading when made.